```json
{
"content": [
{
"type": "paragraph",
"content": "Growth Drivers"
},
{
"type": "list",
"items": [
{ "text": "Precision-medicine tailwinds are accelerating adoption as health systems shift from reactive treatment to predictive prevention, expanding the Custom Genetic Screening market size at a projected double-digit CAGR through 2030.", "level": 1 },
{ "text": "Next-generation sequencing (NGS) unit costs have fallen below $200 per genome-equivalent, enabling labs to bundle multi-gene panels into cost-effective, custom assays that meet payer coverage thresholds and fuel volume-led revenue growth.", "level": 1 }
]
},
{
"type": "paragraph",
"content": "Restraints"
},
{
"type": "list",
"items": [
{ "text": "CMS and commercial payers continue to apply case-by-case prior authorization, delaying revenue recognition and compressing gross margins for Custom Genetic Screening providers that rely on reimbursement rather than cash-pay models.", "level": 1 },
{ "text": "Fragmented variant-interpretation databases create clinical false-positive rates >10%, undermining physician confidence and elongating sales cycles for new custom panels in competitive oncology and prenatal segments.", "level": 1 }
]
},
{
"type": "paragraph",
content: "Opportunities"
},
{
"type": "list",
"items": [
{ "text": "Employer-sponsored population-health contracts—valued at $30–$50 per-member-per-year—are emerging as a high-margin channel forCustom Genetic Screening vendors that can bundle hereditary-risk and pharmacogenomic tests into annual wellness spend.", "level": 1 },
{ "text": "AI-driven polygenic-risk-score (PRS) algorithms now differentiate custom panels beyond single-gene tests, unlocking premium pricing in cardiovascular and diabetes prevention niches where traditional diagnostics underperform.", "level": 1 }
]
},
{
"type": "paragraph",
"content": "Challenges"
},
{
"type": "list",
"items": [
{ "text": "Tightening IVDR and FDA LDT oversight effective 2025 will require full analytical-clinical validity dossiers, forcing mid-tier labs to allocate >15% of annual opex to regulatory compliance or exit the EU and US Custom Genetic Screening market.", "level": 1 },
{ "text": "Supply-chain concentration on Illumina’s sequencing ecosystem exposes providers to reagent price hikes of 8–12% YoY, compressing EBITDA margins just as price competition intensifies among growth-stage competitors.", "level": 1 }
]
}
]
}
```
